What class of compound is Thymosin Alpha-1?

Thymosin Alpha-1 is classified as a Synthetic thymic peptide. Within this class, alternative names and analogues include Zadaxin, Tα1. The class-level pharmacology shapes both the clinical applications and the safety profile; the protocol / scheduling / cycling literature treats Thymosin Alpha-1 alongside its class peers when evaluating relative merits.

What should I look for in Thymosin Alpha-1 sourcing and quality?

Acceptable Thymosin Alpha-1 certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 3108 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

What is the standard dosing protocol for Thymosin Alpha-1?

Conventional Thymosin Alpha-1 dosing is 1.6 mg 2x weekly subq via subq. For scheduling and cycle use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Is Thymosin Alpha-1 safe during pregnancy or breastfeeding?

Thymosin Alpha-1, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Home/ Compounds/ Thymosin Alpha-1

Thymosin Alpha-1

Protocol

For protocol designers building Thymosin Alpha-1 into a multi-compound regimen, the practical questions are pharmacokinetic compatibility, route compatibility, receptor non-overlap, and operational scheduling around real-world constraints (travel, meals, training). The 1.6 mg 2x weekly subq dose at ~2 hr half-life informs which scheduling pattern fits.

Protocol / Scheduling / Cycling Applications

Maintenance PhaseStorage During CycleWeekly TimingOff-TimeWash-Out

Key Takeaways

Scheduling lens: Thymosin Alpha-1's ~2 hr half-life via subq places it in the daily-dosing bucket.
Mechanism: Activates innate immunity via TLR2 and TLR9 signalling on dendritic cells.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

Activates innate immunity via TLR2 and TLR9 signalling on dendritic cells. Promotes T-helper 1 polarisation. Enhances NK cell function. Used as immune adjuvant in chronic viral infection, cancer treatment, and post-sepsis recovery. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for Thymosin Alpha-1.

Cycle length and off-cycle planning

Standard Thymosin Alpha-1 cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any Thymosin Alpha-1 protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most Thymosin Alpha-1 schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Daily and weekly timing

Thymosin Alpha-1 with a ~2 hr half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 2x weekly SubQ, with consistency mattering more than the absolute clock time of any single dose.

Protocol / Scheduling / Cycling Applications

Stack Scheduling

For stack scheduling scheduling, Thymosin Alpha-1 is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Travel Considerations

The most-asked scheduling question for Thymosin Alpha-1 in travel considerations is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Maintenance Phase

Schedule design for Thymosin Alpha-1 in maintenance phase starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Protocol Calendar

For protocol calendar scheduling, Thymosin Alpha-1 is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	1.6 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1.6 mg	4–6 weeks initial cycle
Protocol focus	SubQ	1.6 mg	2x weekly SubQ
Maintenance phase	SubQ	1.6 mg	Ongoing with periodic pauses

Dose timing for Thymosin Alpha-1 is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Thymosin Alpha-1 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

Thymosin Alpha-1 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Thymosin Alpha-1's mechanism in protocol / scheduling / cycling protocols.
Thymosin Alpha-1 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Thymosin Alpha-1's mechanism in protocol / scheduling / cycling protocols.
Thymosin Alpha-1 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Thymosin Alpha-1's mechanism in protocol / scheduling / cycling protocols.
Thymosin Alpha-1 + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Thymosin Alpha-1's mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved (approved in 30+ countries) Research: Multiple Phase III; Cochrane review supports use in HBV/HCV

Excellent. Rare site reactions.

Lens-specific safety considerations for protocol / scheduling / cycling use of Thymosin Alpha-1: Excellent. Rare site reactions. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Thymosin alpha-1 in chronic hepatitis

PMID 17407076

Supporting

Thymosin alpha-1 immunomodulation

PMID 28847497

Thymosin Alpha-1 vs Related Peptides

Compound	Profile	Onset	Best For
Thymosin Alpha-1	Synthetic thymic peptide	~2 hr	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

What if I miss a dose?

Single missed doses are not consequential for most peptide schedules. Resume the next scheduled dose; do not double-dose. Multiple consecutive missed doses (3+) effectively start an off-period and warrant re-evaluating cycle progress before resuming.

Stack timing relative to training and meals?

Fasted dosing for GH-axis and AMPK-engaging compounds; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it. Training-day-only versus daily dosing depends on the compound and the volume of training; verify against the specific protocol.

Daily timing for Thymosin Alpha-1?

Pragmatic timing depends on pharmacokinetics: single daily dose for moderate half-life. Consistent timing matters more than the absolute clock time of any single dose.

When to integrate Thymosin Alpha-1 into an existing stack?

Add one new compound at a time, with at least 2 weeks of isolated dosing to establish individual response, before layering additional compounds. This approach prevents stack complexity from masking individual contributions and makes troubleshooting tractable.

How does Thymosin Alpha-1's half-life affect dosing?

Thymosin Alpha-1 has a plasma half-life of ~2 hr, which is moderate, supporting once-daily dosing in most protocols. The receptor occupancy curve under 2x weekly subq dosing at 1.6 mg per dose explains the typical onset timeline for scheduling and cycle endpoints.

How long until I see results from Thymosin Alpha-1?

Acute effects from Thymosin Alpha-1 appear within the first week for downstream physiological adaptation. scheduling and cycle endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

Clinical Protocol

Start a Thymosin Alpha-1 Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified Thymosin Alpha-1 and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 3108 Da
Sequence length: 28 aa
Half-life: ~2 hr
WADA: Not on prohibited list
FDA: Unapproved (approved in 30+ countries)
Research: Multiple Phase III; Cochrane review supports use in HBV/HCV

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Thymosin Alpha-1 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for Thymosin Alpha-1

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised